Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYZK4776
Stock Name / FundiShares Healthcare Innovation UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerDRDR(GBX) LSE
ETF Ticker2B78(EUR) F
ETF Ticker2B78.DE(EUR) CXE
ETF TickerDRDR.LS(GBX) CXE
ETF TickerHEAL.AS(EUR) CXE
ETF TickerHEAL.LS(USD) CXE
ETF TickerHEALz(USD) CXE
ETF TickerHEAL(EUR) ETF Plus
ETF TickerDRDR.L(GBP) LSE

Holdings detail for PTCT

Stock NamePTC Therapeutics Inc
TickerPTCT(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS69366J2006
LEI549300UJLWOIWFDGB318

Show aggregate PTCT holdings

News associated with PTCT

Bank of America Issues Pessimistic Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock Price
PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price objective reduced by Bank of America from $82.00 to $76.00 in a research report released on Wednesday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Several other brokerages have also issued reports on PTCT. Wall Street Zen lowered PTC Therapeutics from a […] - 2025-08-21 04:58:55
PTC Therapeutics (NASDAQ:PTCT) Price Target Lowered to $73.00 at Wells Fargo & Company
PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price objective trimmed by Wells Fargo & Company from $79.00 to $73.00 in a research report released on Wednesday morning,Benzinga reports. The firm currently has an overweight rating on the biopharmaceutical company’s stock. Other equities analysts also recently issued reports about the company. Cantor Fitzgerald increased their […] - 2025-08-21 04:58:48
Noteworthy Monday Option Activity: ADBE, PTCT, RUM
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Adobe Inc (Symbol: ADBE), where a total of 32,627 contracts have traded so far, representing approximately 3.3 million underlying shares. That amounts to about 95.9% of - 2025-08-11 16:29:24
Natixis Advisors LLC Boosts Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)
Natixis Advisors LLC increased its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 26.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,220 shares of the biopharmaceutical company’s stock after buying an additional 3,160 shares during the quarter. Natixis […] - 2025-08-11 05:47:02
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Rating of “Moderate Buy” by Brokerages
Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the fifteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, four have given a hold rating, nine have issued a buy […] - 2025-08-11 05:11:00
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $80.00
PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price target lifted by UBS Group from $71.00 to $80.00 in a research note released on Tuesday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. PTCT has been the topic of several other reports. Citigroup increased their target price on shares of PTC […] - 2025-08-01 05:49:00
PTC Therapeutics (NASDAQ:PTCT) Price Target Raised to $120.00
PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price objective lifted by Cantor Fitzgerald from $112.00 to $120.00 in a research note issued to investors on Tuesday,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock. Cantor Fitzgerald also issued estimates for PTC Therapeutics’ FY2025 earnings at $8.16 EPS and FY2026 earnings […] - 2025-08-01 05:48:59
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Y Intercept Hong Kong Ltd
Y Intercept Hong Kong Ltd lowered its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 54.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,981 shares of the biopharmaceutical company’s stock after selling 6,043 shares during the quarter. Y Intercept Hong […] - 2025-07-31 04:39:00
Truist Financial Issues Positive Forecast for PTC Therapeutics (NASDAQ:PTCT) Stock Price
PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price objective increased by Truist Financial from $80.00 to $86.00 in a report published on Tuesday morning,Benzinga reports. Truist Financial currently has a buy rating on the biopharmaceutical company’s stock. PTCT has been the topic of a number of other research reports. Wells Fargo & Company lifted […] - 2025-07-30 05:06:48
Bank of America Forecasts Strong Price Appreciation for PTC Therapeutics (NASDAQ:PTCT) Stock
PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price target increased by Bank of America from $68.00 to $84.00 in a research report released on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. A number of other equities analysts have also weighed in on the company. Royal Bank […] - 2025-07-30 04:22:59
Barclays Forecasts Strong Price Appreciation for PTC Therapeutics (NASDAQ:PTCT) Stock
PTC Therapeutics (NASDAQ:PTCT – Free Report) had its price objective upped by Barclays from $42.00 to $46.00 in a report published on Tuesday,Benzinga reports. The brokerage currently has an equal weight rating on the biopharmaceutical company’s stock. Several other analysts also recently commented on PTCT. Robert W. Baird lowered their price objective on PTC Therapeutics […] - 2025-07-30 04:22:55
PTC Therapeutics (NASDAQ:PTCT) Shares Gap Up After Analyst Upgrade
PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report)’s stock price gapped up prior to trading on Tuesday after Truist Financial raised their price target on the stock from $80.00 to $86.00. The stock had previously closed at $44.34, but opened at $47.50. Truist Financial currently has a buy rating on the stock. PTC Therapeutics shares […] - 2025-07-30 02:35:02
New York State Common Retirement Fund Buys 2,000 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)
New York State Common Retirement Fund boosted its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 8.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,421 shares of the biopharmaceutical company’s stock after acquiring an additional 2,000 shares […] - 2025-07-25 05:44:49
Cerity Partners LLC Acquires Shares of 12,581 PTC Therapeutics, Inc. (NASDAQ:PTCT)
Cerity Partners LLC bought a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 12,581 shares of the biopharmaceutical company’s stock, valued at approximately $641,000. A number of other institutional investors have […] - 2025-07-25 04:50:54
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Rating of “Moderate Buy” by Brokerages
PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) has earned an average recommendation of “Moderate Buy” from the fifteen ratings firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, nine have assigned a buy recommendation and one […] - 2025-07-22 03:29:02
PTC Therapeutics, Inc. (NASDAQ:PTCT) Holdings Cut by Bank of New York Mellon Corp
Bank of New York Mellon Corp lowered its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 0.2% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 216,443 shares of the biopharmaceutical company’s stock after selling 439 shares during the period. […] - 2025-07-21 04:26:50
PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock Position Decreased by Teacher Retirement System of Texas
Teacher Retirement System of Texas decreased its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 8.9% during the first quarter, HoldingsChannel.com reports. The fund owned 18,681 shares of the biopharmaceutical company’s stock after selling 1,830 shares during the period. Teacher Retirement System of Texas’ holdings in PTC Therapeutics were worth $952,000 […] - 2025-07-15 04:24:39
10,287 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Purchased by Allspring Global Investments Holdings LLC
Allspring Global Investments Holdings LLC bought a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) during the first quarter, HoldingsChannel reports. The institutional investor bought 10,287 shares of the biopharmaceutical company’s stock, valued at approximately $524,000. A number of other hedge funds have also recently bought and sold shares of PTCT. […] - 2025-07-11 04:31:12
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Purchased by Diversified Trust Co
Diversified Trust Co boosted its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 2.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,147 shares of the biopharmaceutical company’s stock after buying an additional 329 shares during the period. […] - 2025-06-30 05:10:54
PTC Therapeutics (NASDAQ:PTCT) Coverage Initiated at Truist Financial
Equities researchers at Truist Financial started coverage on shares of PTC Therapeutics (NASDAQ:PTCT – Get Free Report) in a research report issued to clients and investors on Tuesday, Marketbeat.com reports. The firm set a “buy” rating and a $80.00 price target on the biopharmaceutical company’s stock. Truist Financial’s target price points to a potential upside […] - 2025-06-19 02:42:49
Pallas Capital Advisors LLC Makes New $353,000 Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT)
Pallas Capital Advisors LLC purchased a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 6,925 shares of the biopharmaceutical company’s stock, valued at approximately $353,000. Several other institutional […] - 2025-06-13 05:38:53
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Purchased by GAMMA Investing LLC
GAMMA Investing LLC lifted its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 9,393.9% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 48,514 shares of the biopharmaceutical company’s stock after acquiring an additional 48,003 shares during the quarter. GAMMA Investing LLC’s holdings […] - 2025-06-13 04:36:51
Universal Beteiligungs und Servicegesellschaft mbH Takes Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)
Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 108,345 shares of the biopharmaceutical company’s stock, valued at approximately $4,891,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.14% of PTC […] - 2025-06-02 06:10:57
Wells Fargo & Company Boosts PTC Therapeutics (NASDAQ:PTCT) Price Target to $74.00
PTC Therapeutics (NASDAQ:PTCT – Get Free Report) had its price target hoisted by equities research analysts at Wells Fargo & Company from $68.00 to $74.00 in a report released on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price target suggests a potential upside of […] - 2025-05-29 02:31:00
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Recommendation of “Moderate Buy” by Brokerages
PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation, eight have assigned a buy recommendation and one has assigned a […] - 2025-05-28 04:46:51
PTC Therapeutics (NASDAQ:PTCT) Shares Gap Up After Earnings Beat
PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report)’s share price gapped up prior to trading on Wednesday following a better than expected earnings announcement. The stock had previously closed at $36.19, but opened at $39.40. PTC Therapeutics shares last traded at $39.92, with a volume of 455,281 shares trading hands. The biopharmaceutical company reported $10.04 […] - 2025-05-09 02:20:49
Analysts Set PTC Therapeutics, Inc. (NASDAQ:PTCT) PT at $63.92
Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) have earned an average rating of “Moderate Buy” from the fifteen brokerages that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, eight have assigned a buy rating and one has […] - 2025-05-06 02:30:48
48,728 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Purchased by Raymond James Financial Inc.
Raymond James Financial Inc. acquired a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) during the fourth quarter, Holdings Channel reports. The firm acquired 48,728 shares of the biopharmaceutical company’s stock, valued at approximately $2,200,000. Several other institutional investors have also added to or reduced their stakes in the business. Smartleaf Asset Management […] - 2025-05-01 05:01:04
Federated Hermes Inc. Buys New Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT)
Federated Hermes Inc. purchased a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) in the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 47,828 shares of the biopharmaceutical company’s stock, valued at approximately $2,159,000. A number of other hedge funds and other institutional investors have also recently modified their holdings of […] - 2025-04-14 05:15:06
PTC Therapeutics, Inc. (NASDAQ:PTCT) Position Reduced by Prudential Financial Inc.
Prudential Financial Inc. trimmed its position in PTC Therapeutics, Inc. (NASDAQ:PTCT – Free Report) by 5.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 5,620 shares of the biopharmaceutical company’s stock after selling 330 shares during the quarter. Prudential Financial Inc.’s holdings in PTC Therapeutics were worth $254,000 at the end of the most […] - 2025-04-11 05:03:01

iShares Healthcare Innovation UCITS ETF USD (Acc) PTCT holdings

DateNumber of PTCT Shares HeldBase Market Value of PTCT SharesLocal Market Value of PTCT SharesChange in PTCT Shares HeldChange in PTCT Base ValueCurrent Price per PTCT Share HeldPrevious Price per PTCT Share Held
2025-11-11 (Tuesday)96,076USD 7,092,330PTCT holding increased by 128742USD 7,092,3300USD 128,742 USD 73.82 USD 72.48
2025-11-10 (Monday)96,076USD 6,963,588PTCT holding increased by 67253USD 6,963,5880USD 67,253 USD 72.48 USD 71.78
2025-11-07 (Friday)96,076USD 6,896,335PTCT holding decreased by -77822USD 6,896,3350USD -77,822 USD 71.78 USD 72.59
2025-11-06 (Thursday)96,076USD 6,974,157PTCT holding increased by 78782USD 6,974,1570USD 78,782 USD 72.59 USD 71.77
2025-11-05 (Wednesday)96,076USD 6,895,375PTCT holding increased by 389108USD 6,895,3750USD 389,108 USD 71.77 USD 67.72
2025-11-04 (Tuesday)96,076USD 6,506,267PTCT holding decreased by -20176USD 6,506,2670USD -20,176 USD 67.72 USD 67.93
2025-11-03 (Monday)96,076USD 6,526,443PTCT holding decreased by -36509USD 6,526,4430USD -36,509 USD 67.93 USD 68.31
2025-10-31 (Friday)96,076USD 6,562,952PTCT holding increased by 19216USD 6,562,9520USD 19,216 USD 68.31 USD 68.11
2025-10-30 (Thursday)96,076USD 6,543,736PTCT holding increased by 73017USD 6,543,7360USD 73,017 USD 68.11 USD 67.35
2025-10-29 (Wednesday)96,076USD 6,470,719PTCT holding decreased by -13450USD 6,470,7190USD -13,450 USD 67.35 USD 67.49
2025-10-28 (Tuesday)96,076USD 6,484,169PTCT holding increased by 39391USD 6,484,1690USD 39,391 USD 67.49 USD 67.08
2025-10-27 (Monday)96,076USD 6,444,778PTCT holding increased by 65332USD 6,444,7780USD 65,332 USD 67.08 USD 66.4
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of PTCT by Blackrock for IE00BYZK4776

Show aggregate share trades of PTCT

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-10-24SELL-81466.40067.780 67.642USD -55,061 49.85 Loss of -14,482 on sale
2025-09-11BUY40860.96061.110 61.095USD 24,927 48.14
2025-07-08SELL-40747.65048.510 48.424USD -19,709 47.94 Loss of -195 on sale
2025-06-24SELL-40949.62050.570 50.475USD -20,644 47.87 Loss of -1,066 on sale
2025-06-23SELL-40949.60050.000 49.960USD -20,434 47.86 Loss of -860 on sale
2025-06-20BUY3,73450.20051.210 51.109USD 190,841 47.84
2025-06-11SELL-39350.82052.070 51.945USD -20,414 47.67 Loss of -1,679 on sale
2025-05-30SELL-39348.52049.090 49.033USD -19,270 47.47 Loss of -616 on sale
2025-05-21BUY39346.21047.480 47.353USD 18,610 47.51
2025-05-14SELL-2,35846.75047.490 47.416USD -111,807 47.54 Profit of 295 on sale
2025-04-30SELL-39249.84050.325 50.277USD -19,708 47.83 Loss of -958 on sale
2025-04-28SELL-39249.76050.405 50.340USD -19,733 47.80 Loss of -998 on sale
2025-04-25SELL-39249.53050.065 50.011USD -19,605 47.78 Loss of -876 on sale
2025-04-11SELL-2,36442.98043.540 43.484USD -102,796 47.82 Profit of 10,240 on sale
2025-04-08SELL-1,17939.77045.030 44.504USD -52,470 48.05 Profit of 4,184 on sale
2025-04-07BUY86942.82044.985 44.769USD 38,904 48.11
2025-03-31SELL-77450.96052.890 52.697USD -40,787 48.15 Loss of -3,517 on sale
2025-03-21SELL-77257.14057.340 57.320USD -44,251 47.55 Loss of -7,544 on sale
2025-03-12SELL-38853.61053.760 53.745USD -20,853 46.76 Loss of -2,710 on sale
2025-02-28SELL-38855.26055.410 55.395USD -21,493 45.97 Loss of -3,657 on sale
2025-02-25BUY38850.36050.580 50.558USD 19,617 45.73
2025-02-20SELL-38850.38050.665 50.637USD -19,647 45.48 Loss of -2,002 on sale
2025-02-19BUY77650.42551.460 51.356USD 39,853 45.38
2025-02-18BUY38849.44052.950 52.599USD 20,408 45.31
2024-12-30BUY1,04045.77045.950 45.932USD 47,769 43.61
2024-12-06SELL-37948.04049.440 49.300USD -18,685 43.10 Loss of -2,348 on sale
2024-12-04SELL-37949.86051.620 51.444USD -19,497 42.67 Loss of -3,324 on sale
2024-12-03SELL-75850.29054.160 53.773USD -40,760 42.39 Loss of -8,627 on sale
2024-11-21SELL-38142.89043.410 43.358USD -16,519 41.22 Loss of -813 on sale
2024-11-20SELL-38641.96042.790 42.707USD -16,485 41.18 Loss of -588 on sale
2024-11-19SELL-38539.36040.060 39.990USD -15,396 41.29 Profit of 501 on sale
2024-11-18SELL-1,52039.23039.860 39.797USD -60,491 41.42 Profit of 2,467 on sale
2024-11-12SELL-38044.62044.870 44.845USD -17,041 41.21 Loss of -1,383 on sale
2024-11-07SELL-38042.96044.560 44.400USD -16,872 40.84 Loss of -1,355 on sale
2024-11-05SELL-76040.87041.080 41.059USD -31,205 40.62 Loss of -334 on sale
2024-10-28SELL-38040.48041.660 41.542USD -15,786 40.48 Loss of -404 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of PTCT

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19134,8970383,22335.2%
2025-09-18283,3490426,43866.4%
2025-09-171,027,79401,194,00886.1%
2025-09-16193,3750307,40362.9%
2025-09-15322,7199534,13960.4%
2025-09-12385,45374562,96568.5%
2025-09-11284,2840452,60662.8%
2025-09-10278,5554408,67368.2%
2025-09-09468,2780688,80568.0%
2025-09-08283,8270420,01767.6%
2025-09-05346,6620658,62852.6%
2025-09-04461,6161,570706,32765.4%
2025-09-03500,00450703,68571.1%
2025-09-02410,808361623,97565.8%
2025-08-29260,928500368,01170.9%
2025-08-28169,3760286,54559.1%
2025-08-27117,5570225,79352.1%
2025-08-26159,7560292,41254.6%
2025-08-25184,3883278,80266.1%
2025-08-22212,2920337,12163.0%
2025-08-21110,0900199,27855.2%
2025-08-20214,8640342,11162.8%
2025-08-19574,175771,073,50653.5%
2025-08-18264,556175600,47344.1%
2025-08-15276,2360451,33761.2%
2025-08-14261,1060447,80158.3%
2025-08-13429,1970681,30463.0%
2025-08-12174,7390313,20955.8%
2025-08-11186,8746,675467,51140.0%
2025-08-08428,3251,746852,88150.2%
2025-08-07147,599144300,02149.2%
2025-08-0682,60020193,16742.8%
2025-08-05182,572112369,25749.4%
2025-08-04134,4690278,38048.3%
2025-08-01173,4700295,78658.6%
2025-07-31371,85250836,67944.4%
2025-07-30349,32275666,75252.4%
2025-07-29539,0072581,083,83649.7%
2025-07-28238,8930371,80364.3%
2025-07-25273,7870463,68359.0%
2025-07-2495,24840211,84045.0%
2025-07-23117,8270221,68053.2%
2025-07-22199,7160323,57861.7%
2025-07-21108,8530162,43967.0%
2025-07-18122,0370172,36370.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.